Mixed
Opicinumab: slow disability worsening in relapsing and progressive MS
relapsing and progressive MS · Remyelination / oligodendrocyte repair
Controlled trials disagree.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 682
How the verdict was reached
Mixed phase 2 results
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| SYNERGY | Phase 2 | 419 | 2013 | Met its main goal | Counted |
| AFFINITY | Phase 2 | 263 | 2017 | Stopped: not working | Counted |
Counted: 2. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Mixed
Related hypotheses
- Clemastine: repair myelin in relapsing and progressive MS
- Gsk239512: repair myelin in relapsing and progressive MS
- Elezanumab: slow disability worsening in relapsing and progressive MS
- Clemastine: reduce relapses and new lesions in relapsing and progressive MS
- Gsk239512: reduce relapses and new lesions in relapsing and progressive MS
Assembled by software from public sources.